3,3’-二己基含氧碳菁碘代物

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 中文名称: 3,3’-二己基含氧碳菁碘代物
• 中文别名: 碘代3,3'-二己氧基羰花青；3,3′-二己基含氧碳菁碘代物
• 英文名称: 3,3'-dihexyloxacarbocyanine iodide
• 英文别名: 3,3′-dihexyloxacarbocyanine iodide；(2Z)-3-hexyl-2-[(Z)-3-(3-hexyl-1,3-benzoxazol-3-ium-2-yl)prop-2-enylidene]-1,3-benzoxazole;iodide
• 化学式: C₂₉H₃₇N₂O₂*I
• 分子量: 572.529
• InChiKey: XVLXYDXJEKLXHN-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  4.64
• 重原子数：
  34
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3,3’-二己基含氧碳菁碘代物 、 tetrabutylammonium bis(1,3-dithiole-2-thione-4,5-dithiolate)niccolate(III) 以 乙腈 为溶剂， 生成 β-DiCC[Ni(dmit)₂]
  参考文献：
  名称：

  Capacitor-like Behavior of Molecular Crystal β-DiCC[Ni(dmit)₂]

  摘要：

  β-DiCC[Ni(dmit)2]（dmit：1,3-二硫代-2-硫酮-4,5-二硫醇，DiCC：3,3′-二己基氧杂羰花青）是一种具有氧化还原活性的电荷转移盐。当施加电压时，它会产生可逆的、滞后的固态电解反应，表现出类似电容器的电反应。根据电子自旋共振谱、电阻率行为和紧密结合带计算，可以通过施加电压精细、可逆地控制 DiCC+ 和 [Ni(dmit)2]- 分子之间的氧化还原平衡。

  DOI：

  10.1246/cl.140309

文献信息

• [EN] TRIAZOLONE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE TRIAZOLONE ET LEURS UTILISATIONS
  申请人：INCEPTION 2 INC

  公开号：WO2013134562A1

  公开（公告）日：2013-09-12

  The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist.

  本发明涉及的化合物属于式(I)及其药学上可接受的盐，可用于治疗前列腺、乳腺、结肠、胰腺、人类慢性淋巴细胞白血病、黑色素瘤和其他癌症。该发明还包括含有式(I)化合物的治疗有效量或其药学上可接受的盐的药物组合物。本发明还涉及治疗前列腺、乳腺、卵巢、肝脏、肾脏、结肠、胰腺、人类慢性淋巴细胞白血病、黑色素瘤和其他癌症的方法。本发明还涉及治疗前列腺、乳腺、结肠、胰腺、慢性淋巴细胞白血病、黑色素瘤和其他癌症的方法，包括给予选择性PPARα拮抗剂的治疗有效量。本发明的化合物和药物组合物还可用于治疗病毒感染，如HCV感染和HIV感染。本发明还涉及一种预防急性和慢性骨髓性白血病以及其他癌症发作和/或复发的方法，包括给予选择性PPARα拮抗剂的治疗有效量。
• NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS
  申请人：Guichard Gilles

  公开号：US20100183642A1

  公开（公告）日：2010-07-22

  The invention concerns a compound of formula (I), wherein Y represents a macrocycle whereof the cycle comprises 9 to 36 atoms, and is functionalized by three amine or COOH functions; R c represents a group of formula H—X a —X b —X c —X d —X e —(X f ) i —, wherein i represents 0 or 1, X n is in particular selected among lysine, arginine, ornithine residues, X b is in particular selected among glycine, asparagine, L-proline or D-proline residues, X c et X d are in particular selected among tyrosine, phenylalanine or 3-nitrotyrosine residues, X e et X f are in particular selected among the following amino acid residues: NH 2 —(CH 2 ) n —COOH, n ranging from 1 to 10 or NH 2 —(CH 2 —CH 2 —O) m —CH 2 CH 2 COOH, m ranging from 3 to 6, provided that one at least of the amino acid residues X a , X b , X c and X d is different from the corresponding amino acid in the sequence of the natural CD40 143 Lys-Gly-Tyr-Tyr 146 fragment

  该发明涉及一种化合物，其化学式为（I），其中Y代表一个大环，该环包含9至36个原子，并且通过三个胺基或COOH功能官能化；Rc代表一个化学式为H—Xa—Xb—Xc—Xd—Xe—（Xf）i—的基团，其中i代表0或1，Xn特别选自赖氨酸、精氨酸、鸟氨酸残基之一，Xb特别选自甘氨酸、天冬氨酸、L-脯氨酸或D-脯氨酸残基之一，Xc和Xd特别选自酪氨酸、苯丙氨酸或3-硝基酪氨酸残基之一，Xe和Xf特别选自以下氨基酸残基之一：NH2—（CH2）n—COOH，其中n取1至10之间的值，或NH2—（CH2—CH2—O）m—CH2CH2COOH，其中m取3至6之间的值，前提是氨基酸残基Xa、Xb、Xc和Xd中至少有一个与天然CD40143Lys-Gly-Tyr-Tyr146片段中相应的氨基酸不同。
• [EN] COMPOUNDS FOR INDUCING CELLULAR APOPTOSIS<br/>[FR] COMPOSÉS ENTRAÎNANT L'APOPTOSE
  申请人：QUEEN MARY & WESTFIELD COLLEGE

  公开号：WO2010125343A1

  公开（公告）日：2010-11-04

  The present invention provides isoquinoline, tetrahydroisoquinoline and tetrahydropyridopyrimidine compounds that induce cell death by apoptosis and uses of the compounds in medicine, expecially their use for treating cancer and other diseases.

  本发明提供了诱导细胞凋亡的异喹啉、四氢异喹啉和四氢吡啶吡咯啉化合物，以及这些化合物在医学上的用途，尤其是它们用于治疗癌症和其他疾病的用途。
• FLUORESCENT ENDOPLASMIC RETICULUM TRACKERS FOR LIVE CELL IMAGING OF PATHOGENIC YEAST
  申请人：Ramot at Tel Aviv University Ltd.

  公开号：US20200072711A1

  公开（公告）日：2020-03-05

  Particular 1,2,3-triazole- and 1,2,4-triazole-based compounds can be used as fluorescent probes. The compounds can optionally be substituted with one or two fluorine atoms. The compounds are effective as specific endoplasmatic reticulum (ER)-trackers for live cell imaging in a fungal cell, such as a pathogenic yeast. Compositions including the fluorescent probes can be used in methods for tracking the endoplasmic reticulum in a fungal cell.

  特定的1,2,3-三唑和1,2,4-三唑基化合物可用作荧光探针。这些化合物可以选择性地被一个或两个氟原子取代。这些化合物可作为特定内质网（ER）跟踪剂用于真菌细胞的活细胞成像，如病原性酵母细胞。包括荧光探针的组合物可用于追踪真菌细胞中的内质网的方法。
• [EN] COMBINATIONS FOR THE TREATMENT OF CANCER<br/>[FR] COMBINAISONS POUR LE TRAITEMENT DU CANCER
  申请人：BAYER PHARMA AG

  公开号：WO2014020041A1

  公开（公告）日：2014-02-06

  The present invention relates to combinations of at least two compounds A and B, compound A being an inhibitor of Mps-1 kinase, and compound B being an inhibitor of an anti-apoptotic protein of the Bcl-2 family. Another aspect of the present invention relates to the use of such combinations as described supra for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of cancer. Another aspect of the present invention relates to the use of an anti- apoptotic protein from the Bcl-2 family as a sensitizer of cells to Mps-1 inhibitors. Another aspect of the present invention relates to the use of the ratio of pro-apoptotic and anti-apoptotic proteins from the Bcl-2 family in a biological sample as a biomarker for a Mps-1 kinase inhibitor treatment.

  本发明涉及至少两种化合物A和B的组合，其中化合物A是Mps-1激酶的抑制剂，化合物B是Bcl-2家族抗凋亡蛋白的抑制剂。本发明的另一个方面涉及将这种组合用于制备用于治疗或预防疾病的药物，特别是用于癌症治疗。本发明的另一个方面涉及将Bcl-2家族的抗凋亡蛋白用作细胞对Mps-1抑制剂的敏感剂。本发明的另一个方面涉及将Bcl-2家族的促凋亡和抗凋亡蛋白的比例在生物样本中用作Mps-1激酶抑制剂治疗的生物标志物。